Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis


Efe C., Hagstrom H., Ytting H., Bhanji R. A. , Muller N. F. , Wang Q., ...More

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.15, no.12, pp.1950-1957, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 12
  • Publication Date: 2017
  • Doi Number: 10.1016/j.cgh.2017.06.001
  • Title of Journal : CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
  • Page Numbers: pp.1950-1957

Abstract

BACKGROUND & AIMS: Predniso(lo) ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.